BridgeBio Pharma Investing Activities - Other 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly investing activities - other history and growth rate from 2018 to 2025. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- BridgeBio Pharma investing activities - other for the quarter ending March 31, 2025 was $0M, a 100% decline year-over-year.
- BridgeBio Pharma investing activities - other for the twelve months ending March 31, 2025 was $0.077B, a 217.16% increase year-over-year.
- BridgeBio Pharma annual investing activities - other for 2024 was $0.026B, a 5177.93% decline from 2023.
- BridgeBio Pharma annual investing activities - other for 2023 was $-0.001B, a 100.42% decline from 2022.
- BridgeBio Pharma annual investing activities - other for 2022 was $0.12B, a 778.86% increase from 2021.
BridgeBio Pharma Annual Investing Activities - Other
(Millions of US $) |
| 2024 |
$26 |
| 2023 |
$-1 |
| 2022 |
$120 |
| 2021 |
$14 |
| 2020 |
$-7 |
| 2019 |
$-2 |
| 2018 |
$-19 |
| 2017 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.397B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
